ESP.AS - Esperite N.V.

Amsterdam - Amsterdam Delayed Price. Currency in EUR
0.0630
-0.0019 (-2.93%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Previous Close0.0649
Open0.0649
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0621 - 0.0650
52 Week Range0.0540 - 0.3120
Volume63,295
Avg. Volume697,851
Market Cap2.294M
Beta (3Y Monthly)2.24
PE Ratio (TTM)N/A
EPS (TTM)-0.9230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-05-18
1y Target EstN/A
  • GlobeNewswire

    Esperite N.V.: announces termination of audit engagement in relation to 2018 annual report

    Esperite N.V. (Euronext: ESP, “Esperite”) announces that its statutory auditor, accon avm controlepraktijk B.V. (“Accon”) has terminated the audit engagement in relation to the 2018 annual report due to the non-observance by Esperite of a deadline imposed by Accon. The Board of Esperite considers the termination ineffective due to the lack of a reasonable notice period, and is currently assessing whether to initiate legal proceedings against Accon.

  • GlobeNewswire

    ESPERITE (N.V) WITH CRYOSAVE ANNOUNCES THE RELEASE OF TWO CORD BLOOD STEM CELLS SAMPLES FOR TREATMENTS AND THEREFORE CONFIRMS THE IMPORTANCE OF STEM CELLS IN THE FIELD OF REGENERATIVE MEDICINE.

    Two families wishing to improve the quality of life for their children, have requested the release of their cord blood stem cells units, safely stored with CryoSave, the family Stem Cells Bank fully authorized for autologous and allogenic transplantations by the National Swiss Agency and accredited as a licensed Organ and Tissue Establishment.

  • GlobeNewswire

    ESPERITE N.V. (ESP) publishes its half-year report. Revenues, results and consolidated equity were impacted by adverse market conditions on the stem cell business.

    ESPERITE N.V. (ESP) publishes its half-year report. Revenues, results and consolidated equity were impacted by adverse market conditions on the stem cell business. CEO,.

  • GlobeNewswire

    Esperite N.V.: Update to the market on the publication of the Annual Report 2018

    Esperite N.V. announced on 30 April 2019 that the publication of the Annual Report 2018 will be delayed. The Company made significant progress was confident in its ability to publish the Annual Report 2018 and Half Year Results 2018 before the end of June 2019. Despite the entire dedication of the company’s finance team, Esperite has to announce further delays and hope to be able to publish its annual report before July 7th 2019.

  • GlobeNewswire

    ESPERITE (ESP) announces termination of negotiations regarding proposed sale of stem cell banking business to PBKM

    Esperite N.V. (Euronext: ESP, “Esperite”) announces today that the negotiations with Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the proposed sale of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Sale) has been terminated by PBKM. The terms of the Proposed Sale agreed between the respective executive boards of the parties did not receive approval by the supervisory board of PBKM. The board of directors of Esperite continues its evaluation of a broad range of strategic alternatives for its stem cell banking business and will seek reimbursement by PBKM for the legal costs incurred by Esperite during the negotiations of the Proposed Sale.

  • GlobeNewswire

    ESPERITE (ESP) negotiates 18-month extension for EUR 4,750,000 in unsecured convertible loan notes

    Esperite N.V. (Euronext: ESP, “Esperite”) is pleased to announce that it has agreed an extension of the maturity dates for EUR 4,750,000 in unsecured convertible loan notes (the Loan Notes). Esperite’s CEO, Mr. Frederic Amar, (in)directly holds EUR 3,350,000 of the Loan Notes, the remaining EUR 1,400,000 in Loan Notes are held by third party investors. The new Loan Notes will bear interest at a rate of 15% per year, payable monthly and are convertible into Esperite shares from 1 January 2020 (or at the earlier occurrence of a limited number of events) until maturity at an initial conversion price of EUR 0.10.

  • GlobeNewswire

    ESPERITE (ESP) resumes negotiations regarding proposed sale of stem cell banking business to PBKM

    Amsterdam, The Netherlands – 13 June 2019 Esperite N.V. (Euronext: ESP, “Esperite”) announces today that it has resumed negotiations  with Polski Bank Komórek.

  • GlobeNewswire

    Esperite NV (ESP) introduces Jouvene - Swiss Medicine Quintessence, the first combined offer of Stem Cell long term storage and highly accurate Whle Genome Sequencing for Consumer distribution.

    Jouvene’s new innovative offer will empower people with disease prevention, detection, diagnosis, treatment and management. With more than 10,000 diseases and medical conditions linked to DNA mutations, Whole Genome Sequencing is the Gold Standard for Genetic Diagnostic and the way of personalized medicine. Whole Genome Sequencing (WGS) is the state-of-the-art technology to decrypt and comprehend an individual in a Single Essay.  The complete DNA make-up of an individual is revealed in order to  identify the diseases that are most likely to affect him and what are the possible ways to prevent these diseases.

  • GlobeNewswire

    ESPERITE (ESP) announces termination of MoU regarding proposed sale of stem cell banking business to PBKM due to lack of agreement on the terms of the sale

    Esperite N.V. (Euronext: ESP, “Esperite”) announces today that the Memorandum of Understanding (MoU) between Esperite and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the proposed sale of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Sale) has been terminated due to parties’ lack of agreement on the terms of the sale. As a result, the exclusivity granted by Esperite to PBKM in relation to the Proposed Sale also terminated with immediate effect. The board of directors of Esperite is currently evaluating a broad range of strategic alternatives for its stem cell banking business.

  • GlobeNewswire

    ESPERITE (ESP) announces listing measure by Euronext due to delay in publication of its 2018 annual report (as announced on 30 April 2019)

    Esperite N.V. (Euronext: ESP, “Esperite”) announces today that it has received a notice from Euronext that its ordinary shares will be transferred to trading group JG, a special segment for securities subject to listing measures. ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.

  • GlobeNewswire

    Esperite N.V. (ESP) : Update to the market on the publica-tion of the Annual Report 2018 and The Cell Factory cur-rent configuration.

    Esperite N.V. announced on 30 April 2019 that the publication of the Annual Report 2018 will be delayed.  The Company has made significant progress and it is confident in its ability to publish the Annual Report 2018 and Half Year Results 2018 before the end of June 2019. Esperite N.V. with his subsidiary The Cell Factory wants to confirm that the recent adverse situation does not affect the company’s R&D projects in the field of Exosomes and Micro Vesicules. Esperite N.V. is in full control of the Intellectual Property and Patents related to these projects.

  • GlobeNewswire

    Esperite N.V. (ESP) : Update to the market on the publication of the Annual Report 2018

    Esperite N.V. announced on 22 February 2019 that the Company had signed an exclusive agreement regarding the potential acquisition (the Proposed Acquisition) of Cryo Save’s family stem cell banking business by PBKM (Famicord Group). The Proposed Acquisition is a key milestone with regard to the future and strategy of the Company and is subject to the outcome of a due diligence process which is a complex operation. As a consequence additional time is needed to publish the Annual Report 2018.

  • GlobeNewswire

    ESPERITE (ESP) announces private placement of convertible loan notes to the European Select Growth Opportunities Fund

    Esperite N.V. (Euronext: ESP, “Esperite”) announces today a EUR 250,000 private placement of 25 convertible notes with a principal amount of EUR 10,000 each (the “Notes”), with 978,260 share subscription warrants attached with a strike price of EUR 0.115 (the “Warrants”). The Notes and Warrants were issued to European Select Growth Opportunities Fund, a fund based in Australia (the “Investor”). The placement of the Notes and Warrants is the 26th tranche launched under the issuance agreement entered into by Esperite with the Investor on 8 March 2017 (the “Issuance Agreement”).

  • GlobeNewswire

    Esperite N.V. (ESP) with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of Bronchopulmonary Dysplasia.

    CF-MEV-132 drug candidate belongs to the CF-MEV family of anti-inflammatory EV drugs produced by The Cell Factory Amsterdam, The Netherlands – 27 February 2019 The Cell.

  • GlobeNewswire

    ESPERITE NV (ESP) AND PBKM (FAMICORD GROUP) SIGN EXCLUSIVE AGREEMENT REGARDING POTENTIAL ACQUISITION OF CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS.

    Esperite N.V. (ESP.NX) and Polski Bank Komórek Macierzystych S.A. (WSE:PBKM) are pleased to announce that they have entered into an Memorandum of Understanding (MoU) regarding the potential acquisition by PBKM of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Acquisition). The Proposed Acquisition leverages the respective strengths and quality standards of the two publicly traded companies that are both leading in the stem cell banking sector. Cryo-Save is one of the largest and longest operating stem cell bank in Europe, in which store more than 330.000 umbilical cord blood samples and tissues.

  • GlobeNewswire

    ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 24th tranche of investment today

    Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 24th   Tranche of EUR 230,000 is issued as a private placement of 23 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 778,195 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the European Select Growth Opportunities Fund on 8 March 2017 (the "Agreement"). ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000. To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.com,  www.genoma.com and www.cryo-save.com.

  • Is Esperite NV’s (AMS:ESP) CEO Salary Justified?
    Simply Wall St.

    Is Esperite NV’s (AMS:ESP) CEO Salary Justified?

    Frederic Amar has been the CEO of Esperite NV (AMS:ESP) since 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...

  • GlobeNewswire

    ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 23rd tranche of investment today

    Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 23rd   Tranche of EUR 220,000 is issued as a private placement of 22 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 592,814 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the European Select Growth Opportunities Fund on 8 March 2017 (the "Agreement").  Prior to the issuance of the 23rd Tranche, EUR 7,950,000 of Notes out of the total commitment of EUR 9 million under the Agreement have been issued to the Investor and EUR 247,500 share subscription warrants have been exercised by the Investor. ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.

  • GlobeNewswire

    Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.

    The Cell Factory is expecting to complete the syndicate of investors to secure its Series A round as forecasted in their business planning for Q1 2019. The Cell Factory in collaboration with its academic partners have made a significant progress in pre-clinical development of its 1st generation and 2nd generation Extracellular Vesicles (EVs) drug candidates and is ready to start the first-in-man clinical trials in treatment of drug-resistant Crohn`s disease (CF-MEV-107).

  • GlobeNewswire

    ESPERITE N.V. convenes Annual General Meeting of Shareholders

    Esperite N.V. (Euronext: ESP, "Esperite") announces that it has convened its Annual General Meeting of Shareholders ("AGM") to be held on 8 January 2019 at 14:00 hours CET at Hotel NH Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD, Amsterdam, The Netherlands. The AGM`s convocation notice, agenda and the explanatory notes to the agenda and further AGM materials can be downloaded from Esperite`s website (www.esperite.com) and are available free of charge at Esperite`s offices in Amsterdam, The Netherlands.

  • GlobeNewswire

    ESPERITE (ESP): financial results for 2017 are published.

    ESPERITE N.V. (Euronext: ESP, "Esperite", "the Company" or "the Group") has published today its Annual Report for the year ended 31 December 2017. The 2017 Annual Report is now available on the Company`s website www.esperite.com. Genoma with AGAATA made strong technological progress despite the liquidation of the Swiss Genoma SA. AGAATA in its latest 3rd version is the state of the art in Genetic Diagnostic technology.

  • GlobeNewswire

    ESPERITE (ESP) announces publication of its Annual Report 2017 before 24 November 2018

    Amsterdam, The Netherlands - 19 November 2018 Esperite announces that the preparation of its Annual Report 2017 is now under final review by its auditors and should be published before 24 November 2018. ...

  • GlobeNewswire

    ESPERITE (ESP) expects publication of Annual Report 2017 before 17 November 2018

    Amsterdam, The Netherlands - 09 November 2018 Esperite announces that the preparation of its Annual Report 2017 is nearly finalized and expects the publication of its Annual Report 2017 before 17 November ...

  • GlobeNewswire

    Esperite Group with The Cell Factory, expands its patent portfolio on extra-cellular vesicles biologic drugs in Canada.

    Amsterdam, the Netherlands - 7 November 2018 Esperite`s (Euronext: ESP) biotech company The Cell Factory has obtained the patent for the use of extracellular vesicles (EVs) in the treatment of acute and ...